Upstream Bio (UPB) Net Cash Flow (2023 - 2026)
Upstream Bio (UPB) posted quarterly Net Cash Flow of -$4.9 million for Q1 2026, up 98.09% year-over-year from -$2.5 million in Q1 2025, and down 116.5% quarter-over-quarter from $29.4 million in Q4 2025.
Upstream Bio (UPB) Net Cash Flow (2023 - 2026) Analysis & Trends
Upstream Bio's Net Cash Flow history runs 4 years deep, the most recent figure standing at -$4.9 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 98.09% year-over-year to -$4.9 million; the TTM figure through Mar 2026 stood at $25.4 million (down 36.46% YoY), while the FY2025 annual figure was -$224.3 million, down 174.71% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$4.9 million, down from $29.4 million in the prior quarter.
- The five-year high for Net Cash Flow was $292.9 million in Q4 2024, with the low at -$254.6 million in Q1 2025.
- The 4-year median for Net Cash Flow is $411500.0 (2024), against an average of $5.0 million.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow surged 1463.48% in 2024, then slumped 4584.41% in 2025.
- Upstream Bio's Net Cash Flow stood at -$21.5 million in 2023, then soared by 1463.48% to $292.9 million in 2024, then sank by 89.96% to $29.4 million in 2025, then plunged by 116.5% to -$4.9 million in 2026.
- Business Quant data shows UPB's Net Cash Flow at -$4.9 million in Q1 2026, $29.4 million in Q4 2025, and $26.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Upstream Bio | 387.23 Mn | 387.23 Mn | -3.29 Mn | -17.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.33 Mn |
| Jun 30, 2026 | -17.33 Mn |
| Mar 31, 2026 | -4.85 Mn |
| Mar 31, 2026 | -4.85 Mn |
| Dec 31, 2025 | 29.41 Mn |
| Dec 31, 2025 | 29.41 Mn |
| Sep 30, 2025 | 26.71 Mn |
| Sep 30, 2025 | 26.71 Mn |
| Jun 30, 2025 | -25.85 Mn |
| Jun 30, 2025 | -25.85 Mn |
| Mar 31, 2025 | -254.58 Mn |
| Mar 31, 2025 | -254.58 Mn |
| Dec 31, 2024 | 292.94 Mn |
| Dec 31, 2024 | 292.94 Mn |
| Sep 30, 2024 | -14.19 Mn |
| Sep 30, 2024 | -14.19 Mn |
| Jun 30, 2024 | 15.83 Mn |
| Jun 30, 2024 | 15.83 Mn |
| Mar 31, 2024 | 5.68 Mn |
| Mar 31, 2024 | 5.68 Mn |